Home Cart Sign in  
Chemical Structure| 356057-34-6 Chemical Structure| 356057-34-6

Structure of Darapladib
CAS No.: 356057-34-6

Chemical Structure| 356057-34-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Darapladib is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM.

Synonyms: SB-480848

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Darapladib

CAS No. :356057-34-6
Formula : C36H38F4N4O2S
M.W : 666.77
SMILES Code : O=C(N(CCN(CC)CC)CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)CN(C3=C4CCC3)C(SCC5=CC=C(F)C=C5)=NC4=O
Synonyms :
SB-480848
MDL No. :MFCD18251452
InChI Key :WDPFJWLDPVQCAJ-UHFFFAOYSA-N
Pubchem ID :9939609

Safety of Darapladib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 differentiated macrophages 0.5 µM, 1 µM, 2 µM 24, 48, 72 hours To evaluate the effect of Darapladib on the phenotype of THP-1 differentiated macrophages, results showed that Darapladib treatment significantly increased the expression of M1 marker CD86 and decreased the expression of M2 marker CD206. PMC10824072
Mouse bone marrow-derived macrophages (BMDMs) 0.5 µM, 1 µM, 2 µM To evaluate the effect of Darapladib on the phenotype of BMDMs, results showed that Darapladib treatment significantly increased the expression of M1 marker CD86 and decreased the expression of M2 marker CD206, and enhanced CD8 T cell activation. PMC10824072
C2C12 myotubes 1 μM 48 hours To evaluate the effect of Darapladib on myotube atrophy, results showed that Darapladib partially counteracted C26 conditioned media-induced myotube atrophy. PMC8517355
3T3-L1 adipocytes 1 μM 48 hours To evaluate the effect of Darapladib on adipocyte lipolysis, results showed that Darapladib had no significant effect on C26 conditioned media-induced adipocyte lipolysis. PMC8517355
Bone marrow-derived macrophages (BMDMs) 100 nmol/L 1 hour Darapladib inhibited Ang II-induced NLRP3 inflaμMasome activation and IL-1β secretion in macrophages. PMC8632984

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Repeated and Intermittent Sound Stress (RISS) model Intraperitoneal injection 4 mg/kg Once daily for 8 weeks Darapladib significantly reduced LPC16:0 production after RISS and prevented the development of chronic hypersensitivity. PMC7677496
C57BL/6 mice Subcutaneous and orthotopic HCC models Intraperitoneal injection 5–10 μg/day/mouse Daily for 6 weeks To evaluate the effect of Darapladib on tumor growth in HCC mouse models, results showed that Darapladib significantly inhibited tumor growth and enhanced the efficacy of anti-PD-1 therapy. PMC10824072
Mice C26 tumor-bearing mouse model Oral gavage 500 nM Once daily for 15 days To evaluate the effect of Darapladib on cancer cachexia, results showed that despite significant inhibition of circulating PLA2G7 activity, Darapladib did not effectively improve inflammation and tissue wasting. PMC8517355
C57BL/6J mice Ang II-induced hypertension model Oral 10 mg/kg Once daily until the end of the experiment Darapladib significantly prevented Ang II-induced cardiac fibrosis, ventricular hypertrophy, and cardiac dysfunction, and reduced macrophage infiltration and inflammatory response. PMC8632984
Mice LDLR-deficient mice Oral 50 mg/kg Once daily for 2-3 weeks To investigate the effects of Darapladib on inflammation and atherosclerotic formation in LDLR-deficient mice. Results showed that Darapladib significantly reduced serum lp-PLA2 activity, hs-CRP, and IL-6 levels, and decreased atherosclerotic plaque area. PMC4010081

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02058641 Atherosclerosis PHASE1 COMPLETED 2014-08-18 GSK Investigational Site, Camb... More >>ridge, CB2 0GG, United Kingdom Less <<
NCT00411073 Atherosclerosis PHASE1 COMPLETED - GSK Investigational Site, Evan... More >>sville, Indiana, 47714, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.50mL

0.30mL

0.15mL

7.50mL

1.50mL

0.75mL

15.00mL

3.00mL

1.50mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories